Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. reports news on its life science research and clinical diagnostics products, including instruments, reagents, test systems, specialized quality controls, blood typing, diabetes products, infectious disease products, and Droplet Digital PCR technologies.
Company updates commonly cover quarterly and annual financial results, Clinical Diagnostics and Life Science segment trends, currency and end-market conditions, product portfolio developments, share repurchases, earnings calls, and healthcare investor conferences. Bio-Rad’s customer base includes universities, research institutions, hospitals, biopharmaceutical companies, and clinical, food safety, and environmental quality laboratories.
Bio-Rad (NYSE: BIO) will participate in two investor conferences in May–June 2026, with CFO Roop K. Lakkaraju hosting fireside chats and one-on-one investor meetings.
Events: RBC Capital Markets Global Healthcare Conference on May 19, 2026 at 8:30 AM ET, and Jefferies Global Healthcare Conference on June 3, 2026 at 8:45 AM ET. Live webcasts and replays will be available in the Investor Relations section at bio-rad.com.
Bio-Rad (NYSE: BIO) reported Q1 2026 results: net sales $592.1M (+1.1% YoY; currency-neutral -4.2%). GAAP net loss was $527.1M due to a fair-value change in a Sartorius AG investment; non-GAAP net income was $50.9M and free cash flow was $78.1M. The company updated 2026 non-GAAP guidance to currency-neutral revenue -3.0% to +0.5% and estimated non-GAAP operating margin ~10.0–12.0%.
Bio-Rad (NYSE: BIO) will report first-quarter 2026 financial results on Thursday, April 30, 2026 following market close. Management will hold a conference call at 2:00 PM Pacific / 5:00 PM Eastern that day with dial-in access and a live webcast.
Dial-in numbers and access code are provided, and a webcast replay will be available for up to one year in the company’s Investor Relations "Events & Presentations" section.
Bio-Rad (NYSE: BIO) reported Q4 2025 net sales of $693.2M (+3.9% YoY) and full‑year 2025 revenue of $2,583.2M (+0.7% YoY). Non‑GAAP net income was $270.5M or $9.92 per diluted share; GAAP net income benefited from a fair‑value gain tied to Sartorius AG, producing GAAP net income of $759.9M.
The company recorded a $172.8M impairment of purchased intangibles, generated $532M cash from operations and $375M free cash flow, completed integration of Stilla for expanded ddPCR offerings, and provided 2026 non‑GAAP guidance of ~0.5–1.5% currency‑neutral revenue growth and ~12.0–12.5% non‑GAAP operating margin.
Bio-Rad (NYSE: BIO) will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 after market close. Management will host a conference call at 2:00 PM PT / 5:00 PM ET to discuss results.
To join, dial domestic or international numbers with access code 9562470, or use the live webcast and supplemental presentation in the Investor Relations "Events & Presentations" section. A replay will be available for up to one year.
Bio-Rad (NYSE: BIO / BIO.B) said its CEO Norman Schwartz, COO Jon DiVincenzo, and CFO Roop K. Lakkaraju will hold one-on-one meetings with analysts and investors at J.P. Morgan's 44th Annual Healthcare Conference in San Francisco, CA, January 12–15, 2026.
The meetings are scheduled as part of the company's participation in the conference and are intended to provide investor engagement and updates on corporate strategy and operations.
Bio-Rad (NYSE: BIO) reported Q3 2025 results for the quarter ended September 30, 2025: total net sales $653.0M (+0.5% vs Q3 2024; currency-neutral -1.7%).
GAAP results included a $341.9M net loss (or $(12.70) per diluted share) driven substantially by a change in fair value of its Sartorius investment; Q3 2024 GAAP net income was $653.2M.
On a non-GAAP basis, Q3 net income was $60.8M ($2.26 per share) vs $56.3M ($2.02) in Q3 2024. Company reaffirmed full-year 2025 non-GAAP guidance: currency-neutral revenue growth ~0–1% and non-GAAP operating margin ~12–13%.
Bio-Rad (NYSE: BIO) will report Q3 2025 financial results on Wednesday, October 29, 2025 after market close. Management will host a conference call the same day at 2:00 PM PT / 5:00 PM ET.
Dial-in numbers: (800) 715-9871 (U.S.) or (646) 307-1963 (international); access code 9562470. A live webcast and supplemental earnings presentation will be posted in the Investor Relations > Events & Presentations section at investors.bio-rad.com. A replay of the webcast will be available for up to one year.
Bio-Rad Laboratories (NYSE: BIO) announced the passing of co-founder and Director Emeritus Alice N. Schwartz on September 25, 2025, at age 99. Schwartz co-founded Bio-Rad in 1952 in Berkeley, California, alongside her husband David Schwartz after graduating with a biochemistry degree from UC Berkeley.
A pioneering figure in life science research, Schwartz was instrumental in developing Bio-Rad's first thyroid function test kit in the 1960s, marking the company's entry into clinical diagnostics. Her contributions helped transform Bio-Rad into a global leader in life science research and clinical diagnostics products. She remained an active Board member until 2022.
Bio-Rad Laboratories (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced its executive leadership team's participation in two upcoming investor conferences.
At the 2025 Wells Fargo Healthcare Conference on September 4, Chairman and CEO Norman Schwartz and CFO Roop K. Lakkaraju will participate in a fireside chat and one-on-one meetings. The fireside chat will be webcast live at 12:45 PM ET. Additionally, CFO Roop K. Lakkaraju will attend the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 for one-on-one investor meetings.